Zanidatamab is an anti-HER2 biparatropic bsAb that targets two different HER2 extracellular domains (ECD) of ECD2 and ECD4 simultaneously, and has been approved for previously treated, unresectable or metastatic HER2-positive biliary tract cancer [98,99]. This evidence concerns the gene ERBB2 and biliary tract cancer.